GlassScriptPhysician profile
Palash Asawa
NPI 1275141673
$2,616.08
in general payments reported to CMS, 2019-2025
16 companies · $2,159 in 2025
The $2,159 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $127 · 2024: $330 · 2025: $2,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,921 · Education: $695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,921.18 |
| Education | $694.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $694.90 | 2025 | |
| Daiichi Sankyo INC. | $263.59 | 2024-2025 | Enhertu, Datroway |
| Gilead Sciences, INC. | $263.19 | 2025 | Trodelvy |
| Amgen INC. | $223.55 | 2023-2025 | Blincyto, Nplate |
| Genzyme Corporation | $196.28 | 2025 | |
| Janssen Scientific Affairs, LLC | $161.90 | 2025 | Rybrevant, Darzalex, Carvykti |
| Regeneron Healthcare Solutions, INC. | $145.55 | 2024-2025 | Libtayo |
| Novocure INC. | $123.43 | 2025 | Optune Lua (Novottf-200t) |
| Glaxosmithkline, LLC. | $111.22 | 2025 | Ojjaara |
| Janssen Biotech, INC. | $108.15 | 2024-2025 | Darzalex, Tecvayli, Carvykti |
| Adaptive Biotechnologies Corporation | $105.13 | 2025 | Clonoseq |
| Pfizer INC. | $99.00 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $43.61 | 2025 | |
| Beone Medicines USA, INC. | $27.49 | 2025 | Tevimbra |
| Kite Pharma, INC. | $26.98 | 2023 | Yescarta |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $22.11 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Palash Asawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.